Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-05-01
2008-10-21
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S019000, C546S016000
Reexamination Certificate
active
07439251
ABSTRACT:
There are provided methods for the treatment of diseases involving dysfunction of the peripheral and central nervous system comprising administering one or more spiro compounds. Also provided are pharmaceutical compositions useful in such methods, compounds for use in the preparation of such pharmaceutical compositions, processes for preparing compounds useful in the practice of such methods, and some novel such compounds per se.
REFERENCES:
patent: 3723442 (1973-03-01), Nakanishi et al.
patent: 5534520 (1996-07-01), Fisher et al.
patent: 5852029 (1998-12-01), Fisher et al.
patent: 0 711 292 (2002-01-01), None
patent: WO 85/03866 (1985-09-01), None
English Abstract, Caplus DN 102:226107 Matsuda, Rieko et al 1985.
Data Base Caplus [Online] Chemical Abstracts Service, Columbus Ohio US; 1989 Menendez, J.C. et al; “Synthesis and antibacterial activity of some 1-thia-4, 8-diazaspiro [4.5]decan-3-ones, thiazolo[2,3-a]-3-onesi and 1,3-onesi and 1,3-thiazino [2,3-a] isoquinolin-4-ones” XP002385656.
Data Base Caplus [Online] Chemical Abstract Service, Columbus, Ohio, US 1971 Nakanishi, Michio et al: “Piperidine derivatives. IV. Synthesis of 3-oxo-1-thia-4,8-diazaspiro[4,5]decane derivatives. 2” XP002385657.
Beach et al., Reduction of cerebrospinal fluid amyloid β after systematic administration of M1 muscarinic agonists. Brain Research, 905:220-223, 2001.
Fisher et al., AF150(S) and AF267(b). Journal of Molecular Neuroscience, 19:145-153, 2002.
Fisher, Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists. Jpn. J. Pharmacol. 84:101-112, 2000.
Fisher et al., M1muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: Implications in future therapy. Journal of Molecular Neuroscience, 20(3): 349-356, 2003.
Ikonen and Tanila, Effects of metrifonate on the hippocampal theta rhythm of freely moving intact as MS-lesioned mice. Pharmacology, Biochemistry and Behavior, 69:165-172, 2001.
Bar-Ner Nira
Fisher Abraham
Karton Yishai
Aulakh Charanjit S
Foley & Lardner LLP
Israel Institute for Biological Research
Reiter Stephen E.
LandOfFree
Methods and compositions for treatment of central and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of central and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of central and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4012307